Celularity and DefEYE Partner to Advance Regenerative Therapies in Eye Care with Exclusive License Agreement and In-Kind Investment.

Celularity and DefEYE, Inc. have partnered to advance the growth of regenerative therapies in eye care. DefEYE will launch and scale a portfolio of decellularized biologic solutions for eye care, including Biovance, Interfyl, and collaborative research and development for future commercial products. Celularity granted DefEYE an exclusive sublicense to its ophthalmic biologics portfolio and will be the exclusive contract manufacturer for DefEYE's portfolio of ophthalmic biologics solutions. The partnership aims to drive innovation and access new markets for Celularity's portfolio of commercial products.